Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients. Metastatic castration-resistant prostate ca...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2013-01, Vol.368 (2), p.138-148 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 148 |
|---|---|
| container_issue | 2 |
| container_start_page | 138 |
| container_title | The New England journal of medicine |
| container_volume | 368 |
| creator | Ryan, Charles J Smith, Matthew R de Bono, Johann S Molina, Arturo Logothetis, Christopher J de Souza, Paul Fizazi, Karim Mainwaring, Paul Piulats, Josep M Ng, Siobhan Carles, Joan Mulders, Peter F.A Basch, Ethan Small, Eric J Saad, Fred Schrijvers, Dirk Van Poppel, Hendrik Mukherjee, Som D Suttmann, Henrik Gerritsen, Winald R Flaig, Thomas W George, Daniel J Yu, Evan Y Efstathiou, Eleni Pantuck, Allan Winquist, Eric Higano, Celestia S Taplin, Mary-Ellen Park, Youn Kheoh, Thian Griffin, Thomas Scher, Howard I Rathkopf, Dana E |
| description | Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients.
Metastatic castration-resistant prostate cancer, defined by tumor growth despite a testosterone level of less than 50 ng per deciliter (1.7 nmol per liter), causes approximately 258,400 deaths annually worldwide.
1
,
2
Death of patients with this condition, which typically occurs within 24 to 48 months after the onset of castration resistance, is commonly preceded by a sequence of landmark events associated with deterioration of overall health and worsening symptoms (Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
3
–
7
Among the treatment options for patients with metastatic castration-resistant prostate cancer who have not undergone chemotherapy . . . |
| doi_str_mv | 10.1056/NEJMoa1209096 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1283051584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2879518681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-d9ffd6eb0331f68dca413e6f78326ccb453e51e1f2596140d376869d842d4a933</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRbK0evUpAPEb3K5vssYRalVY96Dlsklma0mTr7kbpv3dLq8WDc5lheHiHeRC6JPiW4ETcPU-e5kYRiiWW4ggNScJYzDkWx2iIMc1inko2QGfOLXEowuUpGlBGaUZSOkTTcdlY5cGaDqKmi-bglfPKN1X0as12gihXXQU2-mr8wvQ-7OGzMb2L8gW0xi_AqvXmHJ1otXJwse8j9H4_ecsf4tnL9DEfz-IqYdjHtdS6FlBixogWWV0pThgInWaMiqoqecIgIUA0TaQgHNcsFZmQdcZpzZVkbISud7lraz56cL5Ymt524WRBaMZwQpKMByreUVX4wVnQxdo2rbKbguBiq634oy3wV_vUvmyh_qV_PAXgZg8oV6mVtkFJ4w5cSomUQhy4tnVFB8v2n4PfJAt_qA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1283051584</pqid></control><display><type>article</type><title>Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Ryan, Charles J ; Smith, Matthew R ; de Bono, Johann S ; Molina, Arturo ; Logothetis, Christopher J ; de Souza, Paul ; Fizazi, Karim ; Mainwaring, Paul ; Piulats, Josep M ; Ng, Siobhan ; Carles, Joan ; Mulders, Peter F.A ; Basch, Ethan ; Small, Eric J ; Saad, Fred ; Schrijvers, Dirk ; Van Poppel, Hendrik ; Mukherjee, Som D ; Suttmann, Henrik ; Gerritsen, Winald R ; Flaig, Thomas W ; George, Daniel J ; Yu, Evan Y ; Efstathiou, Eleni ; Pantuck, Allan ; Winquist, Eric ; Higano, Celestia S ; Taplin, Mary-Ellen ; Park, Youn ; Kheoh, Thian ; Griffin, Thomas ; Scher, Howard I ; Rathkopf, Dana E</creator><creatorcontrib>Ryan, Charles J ; Smith, Matthew R ; de Bono, Johann S ; Molina, Arturo ; Logothetis, Christopher J ; de Souza, Paul ; Fizazi, Karim ; Mainwaring, Paul ; Piulats, Josep M ; Ng, Siobhan ; Carles, Joan ; Mulders, Peter F.A ; Basch, Ethan ; Small, Eric J ; Saad, Fred ; Schrijvers, Dirk ; Van Poppel, Hendrik ; Mukherjee, Som D ; Suttmann, Henrik ; Gerritsen, Winald R ; Flaig, Thomas W ; George, Daniel J ; Yu, Evan Y ; Efstathiou, Eleni ; Pantuck, Allan ; Winquist, Eric ; Higano, Celestia S ; Taplin, Mary-Ellen ; Park, Youn ; Kheoh, Thian ; Griffin, Thomas ; Scher, Howard I ; Rathkopf, Dana E ; COU-AA-302 Investigators</creatorcontrib><description>Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients.
Metastatic castration-resistant prostate cancer, defined by tumor growth despite a testosterone level of less than 50 ng per deciliter (1.7 nmol per liter), causes approximately 258,400 deaths annually worldwide.
1
,
2
Death of patients with this condition, which typically occurs within 24 to 48 months after the onset of castration resistance, is commonly preceded by a sequence of landmark events associated with deterioration of overall health and worsening symptoms (Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
3
–
7
Among the treatment options for patients with metastatic castration-resistant prostate cancer who have not undergone chemotherapy . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1209096</identifier><identifier>PMID: 23228172</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Abiraterone Acetate ; Androstadienes - adverse effects ; Androstadienes - therapeutic use ; Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer therapies ; Clinical trials ; Disease-Free Survival ; Double-Blind Method ; General aspects ; Humans ; Male ; Medical sciences ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Metastasis ; Nephrology. Urinary tract diseases ; Prednisone - adverse effects ; Prednisone - therapeutic use ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - secondary ; Regulatory approval ; Survival Analysis ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The New England journal of medicine, 2013-01, Vol.368 (2), p.138-148</ispartof><rights>Copyright © 2013 Massachusetts Medical Society. All rights reserved.</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-d9ffd6eb0331f68dca413e6f78326ccb453e51e1f2596140d376869d842d4a933</citedby><cites>FETCH-LOGICAL-c530t-d9ffd6eb0331f68dca413e6f78326ccb453e51e1f2596140d376869d842d4a933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1209096$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1283051584?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,2746,2747,26084,27905,27906,52363,54045,64364,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27219966$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23228172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ryan, Charles J</creatorcontrib><creatorcontrib>Smith, Matthew R</creatorcontrib><creatorcontrib>de Bono, Johann S</creatorcontrib><creatorcontrib>Molina, Arturo</creatorcontrib><creatorcontrib>Logothetis, Christopher J</creatorcontrib><creatorcontrib>de Souza, Paul</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Mainwaring, Paul</creatorcontrib><creatorcontrib>Piulats, Josep M</creatorcontrib><creatorcontrib>Ng, Siobhan</creatorcontrib><creatorcontrib>Carles, Joan</creatorcontrib><creatorcontrib>Mulders, Peter F.A</creatorcontrib><creatorcontrib>Basch, Ethan</creatorcontrib><creatorcontrib>Small, Eric J</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Schrijvers, Dirk</creatorcontrib><creatorcontrib>Van Poppel, Hendrik</creatorcontrib><creatorcontrib>Mukherjee, Som D</creatorcontrib><creatorcontrib>Suttmann, Henrik</creatorcontrib><creatorcontrib>Gerritsen, Winald R</creatorcontrib><creatorcontrib>Flaig, Thomas W</creatorcontrib><creatorcontrib>George, Daniel J</creatorcontrib><creatorcontrib>Yu, Evan Y</creatorcontrib><creatorcontrib>Efstathiou, Eleni</creatorcontrib><creatorcontrib>Pantuck, Allan</creatorcontrib><creatorcontrib>Winquist, Eric</creatorcontrib><creatorcontrib>Higano, Celestia S</creatorcontrib><creatorcontrib>Taplin, Mary-Ellen</creatorcontrib><creatorcontrib>Park, Youn</creatorcontrib><creatorcontrib>Kheoh, Thian</creatorcontrib><creatorcontrib>Griffin, Thomas</creatorcontrib><creatorcontrib>Scher, Howard I</creatorcontrib><creatorcontrib>Rathkopf, Dana E</creatorcontrib><creatorcontrib>COU-AA-302 Investigators</creatorcontrib><title>Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients.
Metastatic castration-resistant prostate cancer, defined by tumor growth despite a testosterone level of less than 50 ng per deciliter (1.7 nmol per liter), causes approximately 258,400 deaths annually worldwide.
1
,
2
Death of patients with this condition, which typically occurs within 24 to 48 months after the onset of castration resistance, is commonly preceded by a sequence of landmark events associated with deterioration of overall health and worsening symptoms (Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
3
–
7
Among the treatment options for patients with metastatic castration-resistant prostate cancer who have not undergone chemotherapy . . .</description><subject>Abiraterone Acetate</subject><subject>Androstadienes - adverse effects</subject><subject>Androstadienes - therapeutic use</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>Disease-Free Survival</subject><subject>Double-Blind Method</subject><subject>General aspects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasm Metastasis</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prednisone - adverse effects</subject><subject>Prednisone - therapeutic use</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - secondary</subject><subject>Regulatory approval</subject><subject>Survival Analysis</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1Lw0AQhhdRbK0evUpAPEb3K5vssYRalVY96Dlsklma0mTr7kbpv3dLq8WDc5lheHiHeRC6JPiW4ETcPU-e5kYRiiWW4ggNScJYzDkWx2iIMc1inko2QGfOLXEowuUpGlBGaUZSOkTTcdlY5cGaDqKmi-bglfPKN1X0as12gihXXQU2-mr8wvQ-7OGzMb2L8gW0xi_AqvXmHJ1otXJwse8j9H4_ecsf4tnL9DEfz-IqYdjHtdS6FlBixogWWV0pThgInWaMiqoqecIgIUA0TaQgHNcsFZmQdcZpzZVkbISud7lraz56cL5Ymt524WRBaMZwQpKMByreUVX4wVnQxdo2rbKbguBiq634oy3wV_vUvmyh_qV_PAXgZg8oV6mVtkFJ4w5cSomUQhy4tnVFB8v2n4PfJAt_qA</recordid><startdate>20130110</startdate><enddate>20130110</enddate><creator>Ryan, Charles J</creator><creator>Smith, Matthew R</creator><creator>de Bono, Johann S</creator><creator>Molina, Arturo</creator><creator>Logothetis, Christopher J</creator><creator>de Souza, Paul</creator><creator>Fizazi, Karim</creator><creator>Mainwaring, Paul</creator><creator>Piulats, Josep M</creator><creator>Ng, Siobhan</creator><creator>Carles, Joan</creator><creator>Mulders, Peter F.A</creator><creator>Basch, Ethan</creator><creator>Small, Eric J</creator><creator>Saad, Fred</creator><creator>Schrijvers, Dirk</creator><creator>Van Poppel, Hendrik</creator><creator>Mukherjee, Som D</creator><creator>Suttmann, Henrik</creator><creator>Gerritsen, Winald R</creator><creator>Flaig, Thomas W</creator><creator>George, Daniel J</creator><creator>Yu, Evan Y</creator><creator>Efstathiou, Eleni</creator><creator>Pantuck, Allan</creator><creator>Winquist, Eric</creator><creator>Higano, Celestia S</creator><creator>Taplin, Mary-Ellen</creator><creator>Park, Youn</creator><creator>Kheoh, Thian</creator><creator>Griffin, Thomas</creator><creator>Scher, Howard I</creator><creator>Rathkopf, Dana E</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20130110</creationdate><title>Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy</title><author>Ryan, Charles J ; Smith, Matthew R ; de Bono, Johann S ; Molina, Arturo ; Logothetis, Christopher J ; de Souza, Paul ; Fizazi, Karim ; Mainwaring, Paul ; Piulats, Josep M ; Ng, Siobhan ; Carles, Joan ; Mulders, Peter F.A ; Basch, Ethan ; Small, Eric J ; Saad, Fred ; Schrijvers, Dirk ; Van Poppel, Hendrik ; Mukherjee, Som D ; Suttmann, Henrik ; Gerritsen, Winald R ; Flaig, Thomas W ; George, Daniel J ; Yu, Evan Y ; Efstathiou, Eleni ; Pantuck, Allan ; Winquist, Eric ; Higano, Celestia S ; Taplin, Mary-Ellen ; Park, Youn ; Kheoh, Thian ; Griffin, Thomas ; Scher, Howard I ; Rathkopf, Dana E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-d9ffd6eb0331f68dca413e6f78326ccb453e51e1f2596140d376869d842d4a933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Abiraterone Acetate</topic><topic>Androstadienes - adverse effects</topic><topic>Androstadienes - therapeutic use</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>Disease-Free Survival</topic><topic>Double-Blind Method</topic><topic>General aspects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasm Metastasis</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prednisone - adverse effects</topic><topic>Prednisone - therapeutic use</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - secondary</topic><topic>Regulatory approval</topic><topic>Survival Analysis</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ryan, Charles J</creatorcontrib><creatorcontrib>Smith, Matthew R</creatorcontrib><creatorcontrib>de Bono, Johann S</creatorcontrib><creatorcontrib>Molina, Arturo</creatorcontrib><creatorcontrib>Logothetis, Christopher J</creatorcontrib><creatorcontrib>de Souza, Paul</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Mainwaring, Paul</creatorcontrib><creatorcontrib>Piulats, Josep M</creatorcontrib><creatorcontrib>Ng, Siobhan</creatorcontrib><creatorcontrib>Carles, Joan</creatorcontrib><creatorcontrib>Mulders, Peter F.A</creatorcontrib><creatorcontrib>Basch, Ethan</creatorcontrib><creatorcontrib>Small, Eric J</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Schrijvers, Dirk</creatorcontrib><creatorcontrib>Van Poppel, Hendrik</creatorcontrib><creatorcontrib>Mukherjee, Som D</creatorcontrib><creatorcontrib>Suttmann, Henrik</creatorcontrib><creatorcontrib>Gerritsen, Winald R</creatorcontrib><creatorcontrib>Flaig, Thomas W</creatorcontrib><creatorcontrib>George, Daniel J</creatorcontrib><creatorcontrib>Yu, Evan Y</creatorcontrib><creatorcontrib>Efstathiou, Eleni</creatorcontrib><creatorcontrib>Pantuck, Allan</creatorcontrib><creatorcontrib>Winquist, Eric</creatorcontrib><creatorcontrib>Higano, Celestia S</creatorcontrib><creatorcontrib>Taplin, Mary-Ellen</creatorcontrib><creatorcontrib>Park, Youn</creatorcontrib><creatorcontrib>Kheoh, Thian</creatorcontrib><creatorcontrib>Griffin, Thomas</creatorcontrib><creatorcontrib>Scher, Howard I</creatorcontrib><creatorcontrib>Rathkopf, Dana E</creatorcontrib><creatorcontrib>COU-AA-302 Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ryan, Charles J</au><au>Smith, Matthew R</au><au>de Bono, Johann S</au><au>Molina, Arturo</au><au>Logothetis, Christopher J</au><au>de Souza, Paul</au><au>Fizazi, Karim</au><au>Mainwaring, Paul</au><au>Piulats, Josep M</au><au>Ng, Siobhan</au><au>Carles, Joan</au><au>Mulders, Peter F.A</au><au>Basch, Ethan</au><au>Small, Eric J</au><au>Saad, Fred</au><au>Schrijvers, Dirk</au><au>Van Poppel, Hendrik</au><au>Mukherjee, Som D</au><au>Suttmann, Henrik</au><au>Gerritsen, Winald R</au><au>Flaig, Thomas W</au><au>George, Daniel J</au><au>Yu, Evan Y</au><au>Efstathiou, Eleni</au><au>Pantuck, Allan</au><au>Winquist, Eric</au><au>Higano, Celestia S</au><au>Taplin, Mary-Ellen</au><au>Park, Youn</au><au>Kheoh, Thian</au><au>Griffin, Thomas</au><au>Scher, Howard I</au><au>Rathkopf, Dana E</au><aucorp>COU-AA-302 Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2013-01-10</date><risdate>2013</risdate><volume>368</volume><issue>2</issue><spage>138</spage><epage>148</epage><pages>138-148</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients.
Metastatic castration-resistant prostate cancer, defined by tumor growth despite a testosterone level of less than 50 ng per deciliter (1.7 nmol per liter), causes approximately 258,400 deaths annually worldwide.
1
,
2
Death of patients with this condition, which typically occurs within 24 to 48 months after the onset of castration resistance, is commonly preceded by a sequence of landmark events associated with deterioration of overall health and worsening symptoms (Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
3
–
7
Among the treatment options for patients with metastatic castration-resistant prostate cancer who have not undergone chemotherapy . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>23228172</pmid><doi>10.1056/NEJMoa1209096</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2013-01, Vol.368 (2), p.138-148 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_1283051584 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Abiraterone Acetate Androstadienes - adverse effects Androstadienes - therapeutic use Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer therapies Clinical trials Disease-Free Survival Double-Blind Method General aspects Humans Male Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Metastasis Nephrology. Urinary tract diseases Prednisone - adverse effects Prednisone - therapeutic use Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - secondary Regulatory approval Survival Analysis Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T20%3A01%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abiraterone%20in%20Metastatic%20Prostate%20Cancer%20without%20Previous%20Chemotherapy&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Ryan,%20Charles%20J&rft.aucorp=COU-AA-302%20Investigators&rft.date=2013-01-10&rft.volume=368&rft.issue=2&rft.spage=138&rft.epage=148&rft.pages=138-148&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa1209096&rft_dat=%3Cproquest_cross%3E2879518681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1283051584&rft_id=info:pmid/23228172&rfr_iscdi=true |